Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 901–1,000 of 3,116
Distinct Profiles and New Pharmacological Targets for Heart Failure with Preserved Ejection Fraction
Palazzuoli, A., Severino, P., D’Amato, A., Myftari, V., Tricarico, L., Correale, M., Dattilo, G., Fioretti, F., & Nodari, S. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2507270 · Cited by 10
Zupec, J. F., Munger, R., Scaletta, A., & Quinn, D. H. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.11279 · Cited by 9
Ardehali, H. (2024) · Journal of Clinical Investigation · doi:10.1172/jci186225 · Cited by 9
Sabina, M., & Alsamman, M. (2024) · Cardiology Research · doi:10.14740/cr1600 · Cited by 10
Henney, A. E., Riley, D. R. J., Heague, M., Roberts, C. A., Hydes, T., Anson, M., Hughes, D. M., Alam, U., & Cuthbertson, D. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70169 · Cited by 12
“The applications of these drugs are myriad and include glucose lowering, 1 – 5 weight loss, cardiorenal protection, 6 – 9 and treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) 10 and obstructive sleep apnoea.”
Sonne, N., Roque, M., Zachariassen, L. F., Porsgaard, T., Pors, S. E., Cavalera, M., Jones, C., Osborn, O., Thorbek, D. D., Riis, M. L., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106121 · Cited by 9
Dorneles, G. P., Algeri, E. D. B. D. O., Lauterbach, G., Pereira, M. G., & Fernandes, B. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2303-8558 · Cited by 9
Obesity and Cardiometabolic Disease: Insights From Genetic Studies
Dash, S. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.01.034 · Cited by 11
Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 98
Nutrient-Stimulating Hormone-Based Therapies for Obesity
Cristancho, C., Kim, D. W., & Apovian, C. M. (2024) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.10.006 · Cited by 8
Tian, Z., Soltani, S., Bauersachs, J. K., Schmidt-Ott, K. M., Melk, A., & Schmidt, B. M. W. (2024) · medRxiv · doi:10.1101/2024.03.04.24303751 · Cited by 9
Using Second-Generation Anti-Obesity Medications
Schmitz, S. H., & Aronne, L. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi24-0002 · Cited by 11
Dietary and pharmacological energy restriction and exercise for healthspan extension
Cagigas, M. L., Ciutiis, I. D., Masedunskas, A., & Fontana, L. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.04.001 · Cited by 14
Inzucchi, S. E., Tan, X., Liang, Y. M., Yedigarova, L., Xie, L., & de Havenon, A. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01678-4 · Cited by 12
Kazé, A. D., Bertoni, A. G., Fox, E. R., Hall, M. E., Mentz, R. J., Berry, J. D., & Echouffo-Tcheugui, J. B. (2025) · Diabetes Care · doi:10.2337/dc24-0654 · Cited by 8
Fahoury, A., Kamel‐Abusalha, L. B., Didier, A. J., Wunderly, K. J., Sarrouj, S., Issa, R., Afifi, A. M., & Gupta, R. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.02.043 · Cited by 8
Hasebe, M., Su, C., Kamido, H., Yabe, D., & Yoshiji, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70458 · Cited by 12
“…by race and incorporating all available GLP-1RA CVOTs, including SELECT — which enrolled individuals without diabetes — and the recent SOUL trial, 3,13 our analysis provides the most extensive evaluation to date of GLP-1RA efficacy across populations defined by race and a quantitative assessment…”
Mao, T., Chen, J., Su, T., Xie, L., Qu, X., Feng, R., Pan, Y., Wan, J., Cui, X., Jia, W., et al. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01448-z · Cited by 11
AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026)
Walsh, M. N., Køber, L., Sliwa, K. S., Adamo, M., Agarwal, A., Banerjee, A., Bozkurt, B., Čikeš, M., Damasceno, A., Desai, A. S., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001455 · Cited by 26
Hong, B., Kim, H., Lee, D., & Kim, K. (2025) · Pharmaceuticals · doi:10.3390/ph18071058 · Cited by 11
Kim, M.-K., & Kim, H. S. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.228 · Cited by 10
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review
Sheth, S., Merola, J. F., Weber, B. N., Prussick, R. B., Yeung, J., Liu, C., Glick, B. P., Reddy, S. M., Cook-Bolden, F. E., Wallace, E. B., et al. (2026) · JAMA Dermatology · doi:10.1001/jamadermatol.2026.0859 · Cited by 17
McIntyre, R. S. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20241087 · Cited by 12
Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial
Lusk, J. B., Glover, L., Soneji, S., Granger, C. B., O'Brien, E., & Pagidipati, N. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.05.007 · Cited by 9
Role of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in Patients with Chronic Heart Failure
Llongueras-Espí, P., García‐Romero, E., Colet, J. C., & González‐Costello, J. (2025) · Biomolecules · doi:10.3390/biom15091342 · Cited by 11
Cowart, K., & Carris, N. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16502 · Cited by 7
Soliman, A. R., Saleem, H. M. E., Meligi, A. A. H. E., Naguib, M., Mohamed, R. S., Abdelaziz, G. R., Rakha, M., Abdelghaffar, S., Hamed, A. E., Hammad, H., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01564-w · Cited by 10
Mertens, J., Winter, H. T. D., Dirinck, E. L., Francque, S., & Block, C. E. M. D. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251362497 · Cited by 12
How do drugs such as Ozempic work for weight loss . . . and everything else?
Guenot, M. (2024) · BMJ · doi:10.1136/bmj.q1767 · Cited by 7
Revolution in Stroke Treatment Over 50 Years and Predicting Stroke Care in 2050
Broderick, J. P. (2025) · Stroke · doi:10.1161/strokeaha.125.052583 · Cited by 7
Glucagon-like peptide-1 medicines in neurological and psychiatric disorders
Fang, S., Cui, F., & Drucker, D. J. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102511 · Cited by 12
“89 Rates of non-fatal stroke are reduced in some but not all GLP-1 CVOTs, with meta-analyses demonstrating ∼ 16% reduction in risk of stroke across multiple CVOTs in people with T2D.”
Koufakis, T., Kokkinos, A. D., & le Roux, C. W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70723 · Cited by 9
“Cardiovascular benefits are substantial: the SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events among individuals with obesity but without diabetes [29].”
Spinal afferent neurons: emerging regulators of energy balance and metabolism
Jarrah, M., Tasabehji, D., Fraer, A., & Mokadem, M. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1479876 · Cited by 7
Siniukovich, A., Travlos, C. K., Freedman, S., Mavrakanas, T. A., & Gariani, K. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01831-4 · Cited by 14
Goldman, S. N., Mani, K., Scharfenberger, T., Kleinbart, E. P., Hui, A. T., Ramos, R. D. L. G., Fourman, M. S., & Eleswarapu, A. S. (2025) · North American Spine Society Journal (NASSJ) · doi:10.1016/j.xnsj.2025.100612 · Cited by 17
Rifai, M. A., Al-Mallah, M. H., Blaha, M. J., Patel, J., McEvoy, J. W., Nasir, K., Shahid, I., Patel, K. V., Sharma, G. V., Marrugat, J., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1864 · Cited by 10
Horiuchi, Y., Wettersten, N. W., Asami, M., Yahagi, K., Komiyama, K., Yuzawa, H., Tanaka, J., Aoki, J., & Tanabe, K. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132611 · Cited by 8
Sheth, S., Inestroza, K., Merola, J. F., Weber, B., & Garshick, M. S. (2025) · Journal of Psoriasis and Psoriatic Arthritis · doi:10.1177/24755303251337020 · Cited by 13
Krishnan, S., Srivastava, P. K., Attaluri, J., Nayeri, R., Chatterjee, D., Patel, J., Nsair, A., Budoff, M. J., & Nayeri, A. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12010019 · Cited by 13
Ballatore, A., Gatti, M., Mella, S., Tore, D., Xhakupi, H., Giorgino, F., Saglietto, A., Carmagnola, L., Roagna, E., Ferrari, G. M. D., et al. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11050137 · Cited by 8
Hermel, M. H., Chiou, A., Minhas, A. M. K., Inam, M., Waldman, C. E., Youngblood, E., Mehta, S., Slipczuk, L. N., Sheikh, S. S., Meloche, C., et al. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01193-8 · Cited by 13
Old and new anti-obesity drugs
Dodangeh, S., & Hasani‐Ranjbar, S. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01512-5 · Cited by 8
The impact of semaglutide use for weight loss on transforaminal lumbar interbody fusion outcomes
Khalid, S. I., Mirpuri, P., Massaad, E., Wang, R., Elsamadicy, A. A., Shin, J. H., & Adogwa, O. (2025) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2025.108952 · Cited by 11
Zhang, J., Guan, X., Kong, M.-W., Xia, M., Yu, Y., & Zhang, C. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156433 · Cited by 9
Miao, M., Yang, Y., & Dai, H. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1407721 · Cited by 7
Causes and consequences of discontinuation of GLP1RAs or tirzepatide
Ceriello, A., Prattichizzo, F., Abdullah, A. R. M. S., Grotta, R. L., Berra, C., McGowan, B. M., Jenkins, A., Cohen, N. D., Nauck, M. A., & Russo, G. T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01258-5 · Cited by 23
“…tirzepatide have demonstrated a range of cardiovascular and other benefits in large trials and studies that included people with and without T2DM 12–20 , To our knowledge, only one study assessed the incidence of cardiovascular events in people who stopped GLP1RAs compared with people who used…”
Chiang, C., Wang, K.-L., Cheng, H., Chao, T., & Sung, S. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001263 · Cited by 12
Recomendaciones preventivas vasculares. Actualización PAPPS 2024
Orozco‐Beltrán, D., Brotons-Cuixart, C., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Martín-Rioboó, E., Jordá-Baldó, A., Vicuña, J., & Navarro-Pérez, J. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103123 · Cited by 13
Small-Molecule GLP-1 Receptor Agonists: A Promising Pharmacological Approach
Șeremet, O. C., Pușcașu, C., Andrei, C., Nițulescu, G., Zbârcea, C. E., & Olaru, O. T. (2025) · Medicina · doi:10.3390/medicina61111902 · Cited by 12
“…cardiovascular disease, overweight or obese, the SELECT trial demonstrated that once-weekly subcutaneous semaglutide 2.4 mg significantly reduced the risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke compared with placebo during a mean follow-up of 39.8 months [22].”
InfluentialAn Updated Prioritization of Geroscience- Guided FDA-Approved Drugs Repurposed to Target Aging
Leone, M., & Barzilai, N. (2024) · Medical Research Archives · doi:10.18103/mra.v12i2.5138 · Cited by 12
Goldney, J., & Davies, M. J. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00977-2 · Cited by 7
Addressing the risk of ocular complications of GLP ‐ 1RAs ; a multi‐disciplinary expert consensus
Carter, P., Simó, R., Lövestam‐Adrian, M., Pearce, I., Bain, S. C., Dinah, C., Davies, S. J., Strain, W. D., Burgess, P. I., Gamble, A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70160 · Cited by 16
“3,4 Despite these benefits, the risk of adverse events should be considered.”
Troshina, E. A., Antsiferov, M. B., As, A., Galstyan, G. R., Маркова, Т. Н., Romantsova, T. I., Mazurina, N. V., & Koteshkova, O. M. K. (2025) · Problems of Endocrinology · doi:10.14341/probl13677 · Cited by 14
Connolly, D. L., Collins, E., Ren, H., Ming, S. W. Y., Davidson, J. A., & Bain, S. C. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01715-w · Cited by 8
Mounsey, L. A., Chitsazan, M., Shi, I., Ribeiro, P. H., Parekh, J. K., Roshandelpoor, A., Ndumele, C. E., Allen, N. B., Khan, S. S., Psaty, B. M., et al. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2025.5305 · Cited by 9
Global barriers to decision makers for prioritizing interventions for obesity
Ehlers, L. H., Reinstrup, N. W., Olesen, R. H., Holm, J., McEwan, P. C., & le Roux, C. W. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01650-z · Cited by 12
Treating obesity in patients with depression: a narrative review and treatment recommendation
Kushner, P. R., Kahan, S. I., & McIntyre, R. S. (2025) · Postgraduate Medicine · doi:10.1080/00325481.2025.2478812 · Cited by 10
Cardiovascular effects of anti-obesity medications: the perils and promise
Zheng, H. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000114 · Cited by 7
Cardiovascular effects of tirzepatide
Sumithran, P., Russell, A. W., & Zoungas, S. (2025) · Journal of Endocrinology · doi:10.1530/joe-24-0259 · Cited by 12
Hua, Y., Chen, Z., Cheng, L., Ding, N., Xie, Y., Wu, H., Jing, H., Xu, Y., Wu, Y., & Lan, B. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1615051 · Cited by 7
Advances in the management of obesity and heart failure: latest evidence from clinical trials
Costa, T. A., & Harrington, J. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001214 · Cited by 7
Chao, T.-H., Lin, T., Cheng, C., Wu, Y., Ueng, K., Wu, Y., Lin, W.-W., Leu, H.-B., Cheng, H., Huang, C., et al. (2024) · PubMed Central · doi:10.6515/acs.202409_40(5).20240724a · Cited by 18
Lassen, M. C. H., Ostrominski, J. W., Claggett, B. L., Ndumele, C. E., Biering‐Sørensen, T., Matsushita, K., Selvin, E., Coresh, J., Shah, A. M., Solomon, S. D., et al. (2026) · Circulation · doi:10.1161/circulationaha.125.077894 · Cited by 14
Nong, K., Shi, Q., Xie, X., Wang, Y., Agarwal, A., Guyatt, G. H., Zhang, H., Gao, Y., Khunti, K., le Roux, C. W., et al. (2026) · BMJ · doi:10.1136/bmj-2026-372161 · Cited by 20
“40 Drug availability also varies across jurisdictions—for example, phente rminetopiramate is approved only in the US—which may influence policy and reimbursement decisions.”
BBiomed, Z. L., Raveendran, D., Fourlanos, S., & Chong, E. W. T. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2025.12.022 · Cited by 10
Abdelhamid, M., Abdrabou, M. M., Faris, E., Elkaffas, S. M. H., Hosny, M., & Hassan, A. (2025) · Cardiac failure review · doi:10.15420/cfr.2025.17 · Cited by 12
GLP-1 receptor agonists in heart failure
Vaduganathan, M. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01598-8 · Cited by 8
Wu, R., Xing, B., Zhou, Z., Yu, L., & Wang, H. (2025) · European journal of medical research · doi:10.1186/s40001-025-03124-y · Cited by 9
Huang, S. Y., Tamaroff, J. G., Farber‐Eger, E. H., Chow, N., Siddiqi, H. K., Brinkley, D. M., Menachem, J. N., Rali, A. S., Lindenfeld, J. M., Ooi, H., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102710 · Cited by 17
Wade, F. G., Lentine, K. L., Turk, D., Kirbach, K., Knobloch, T., Schnitzler, M. A., Qureshi, K., Syn, W., & Fleetwood, V. A. (2025) · Clinical Transplantation · doi:10.1111/ctr.70344 · Cited by 9
Zhou, J., Husain, M., Li, Y., Liu, W., Shen, Z., Vilsbøll, T., & Ge, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16621 · Cited by 10
Epidemiology of cardiovascular–kidney–metabolic syndrome
Mavromatis, L. A., & Grams, M. E. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01078-w · Cited by 14
Neff, G. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70148 · Cited by 13
Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity
Gudzune, K. A., Apovian, C. M., Aroda, V. R., Aronne, L. J., Balapattabi, K., Bennett, A. K., ChallaSivaKanaka, S., ElSayed, N. A., Fitch, A., Fitzpatrick, S. L., et al. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0008 · Cited by 27
Self-citationPatel, R., Kokori, E., Olatunji, G. D., Adejumo, F. A., Ukah, J. D., Babalola, A. E., Ndakotsu, A., Abraham, I. C., & Aderinto, N. (2025) · Current Heart Failure Reports · doi:10.1007/s11897-025-00704-1 · Cited by 10
Semaglutide attenuates lipotoxicity-induced cardiac injury by inhibiting Slc27a2 expression
Pan, X., Wang, S., Yang, X., Jia, B., & Chen, S. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111583 · Cited by 7
Dobbie, L. J., Tolvanen, L., Alves, D., Baker, J. L., Bez, N. S., Birney, S., Bogl, L. H., Brown, A., Bullo, M., Clare, K., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00122-1 · Cited by 8
Johnson, C. E., Sussman, W. B., & Weeda, E. R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15809 · Cited by 11
AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026)
Walsh, M. N., Køber, L., Sliwa, K. S., Adamo, M., Agarwal, A., Banerjee, A., Bozkurt, B., Čikeš, M., Damasceno, A., Desai, A. S., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.05.036 · Cited by 14
Ruseva, A., Michalak, W., Fabricatore, A. N., Hartaigh, B. Ó., Zhao, Z., & Umashanker, D. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03320-6 · Cited by 13
Practical application of semaglutide: From evidence-based research to expert decisions
Салухов, В. В., Galstyan, G. R., Khalimov, Y. S., Бакулин, И. Г., Cherkashin, D. V., Shadrichev, F. E., & Sukhotskaia, N. A. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-185 · Cited by 8
Rodríguez-Miguel, A., Fernández‐Fernández, B., Ortíz, A., Gil, M., Rodríguez‐Martín, S., Ruiz‐Hurtado, G., Fernández-Antón, E., Ruilope, L. M., & de Abajo, F. J. (2024) · Pharmaceuticals · doi:10.3390/ph17101299 · Cited by 9
Dahl, J. N., Nielsen, M. B., Rasmussen, L. D., Ivarsen, P., Williams, M. C., Svensson, M. H. S., Birn, H., Bøttcher, M., & Winther, S. (2024) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.124.017066 · Cited by 7
Wang, T., Pate, V., Wyss, R., Buse, J. B., Kosorok, M. R., & Stürmer, T. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae322 · Cited by 10
Gera, A., Latif, F., Borra, V., Naz, S., Mittal, V., Ayoobkhan, F. S., Kumar, T., Wajid, Z., Deb, N., Prasad, T., et al. (2025) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2025.101638 · Cited by 19
Duan, X., Zhang, X., & Sun, B. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02750-4 · Cited by 8
Paggers, L., Mesotten, D., & Stragier, H. (2024) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000002103 · Cited by 8
Definite benefits of GLP-1 receptor agonists: what is the risk of gastroparesis and lung aspiration?
Camilleri, M. (2024) · Gut · doi:10.1136/gutjnl-2024-333036 · Cited by 8
Chronic kidney disease in older adults: challenges and opportunities for the primary care provider
Brady, B. M., Suffoletto, J.-A., Sankary, R., & Chertow, G. M. (2024) · BMC Family Practice · doi:10.1186/s12875-024-02638-4 · Cited by 10
Addressing the Shortage of GLP-1 RA and Dual GIP/GLP-1 RA-Based Therapies—A Systematic Review
Altabas, V., Orlović, Z., & Baretić, M. (2025) · Diabetology · doi:10.3390/diabetology6060052 · Cited by 10
Jansson, A. K., Gómez‐Martín, M., Hedin, L. E., Clarke, E. D., Cross, V., Stanford, J., Taylor, R., Bogl, L. H., de Vlieger, N., Koochek, A., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70077 · Cited by 13
Clinical Role of Epicardial Adipose Tissue
Raggi, P., & Stillman, A. E. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.02.021 · Cited by 14
Boutari, C., Hill, M. A., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156397 · Cited by 7
The extent and predictors of off‐label use of GLP ‐1 receptor agonists for weight loss management
Siudak, Z., Tkaczyk, F. M., Tomaszewska, M., Malinowski, K. P., Szarpak, Ł., & Kowalska‐Bobko, I. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16313 · Cited by 10
Functional and multi-omic aging rejuvenation with GLP-1R agonismPreprint
Huang, J., Kwok, A. J., Li, J. C. Y., Chiu, C. L. H., Ip, B. Y. M., Tung, L. Y., Zheng, X., Chow, H. T., Lo, M. P. S., Li, Z., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.06.592653 · Cited by 6
Park, C., Kim, Y., Raygani, S., & Grunvald, E. L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1630199 · Cited by 7
Advances in incretin therapies for targeting cardiovascular disease in diabetes
Roberts, T. D., Hutchinson, D. S., Wootten, D. L., Blasio, M. J. D., & Ritchie, R. H. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.03.007 · Cited by 7
GLP1-RA and SGLT2-i: Implementation and Insulin Deescalation Strategies
Palani, A., Patel, S., Patel, S., Srivastava, S., Patel, J., Salehin, S., Birnbaum, Y., & Allencherril, J. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07744-8 · Cited by 8
Nicolau, J., Nadal, A., Sanchís, P., Pujol, A., Tamayo, M. I., Sfondrini, G., Grimalt, M., García, P., Nadal, C., & Masmiquel, L. (2025) · Clinical and Experimental Dermatology · doi:10.1093/ced/llaf473 · Cited by 16
Richardson, K. M., Schembre, S. M., Jospe, M. R., Widmer, A., & Silver, H. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16395 · Cited by 13
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
